Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Proteasome inhibitors are novel antitumor agents against multiple myeloma and other malignancies. Despite the increasing clinical application, the molecular basis of their antitumor effect has been poorly understood due to the involvement of the ubiquitin-proteasome pathway in multiple cellular metabolisms. Here, we show that treatment of cells with proteasome inhibitors has no significant effect on nonhomologous end joining but suppresses homologous recombination (HR), which plays a key role in DNA double-strand break (DSB) repair. In this study, we treat human cells with proteasome inhibitors and show that the inhibition of the proteasome reduces the efficiency of HR-dependent repair of an artificial HR substrate. We further show that inhibition of the proteasome interferes with the activation of Rad51, a key factor for HR, although it does not affect the activation of ATM, γH2AX, or Mre11. These data show that the proteasome-mediated destruction is required for the promotion of HR at an early step. We suggest that the defect in HR-mediated DNA repair caused by proteasome inhibitors contributes to antitumor effect, as HR plays an essential role in cellular proliferation. Moreover, because HR plays key roles in the repair of DSBs caused by chemotherapeutic agents such as cisplatin and by radiotherapy, proteasome inhibitors may enhance the efficacy of these treatments through the suppression of HR-mediated DNA repair pathways. [Cancer Res 2007;67(18):8536–43]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“Upon the induction of DSBs, the ATM kinase senses IR-induced DSBs, and immediately becomes activated and autophosphorylated (24).”
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693 · cited 4×
“This RPA-ssDNA complex seems to facilitate the recruitment of ATR-ATRIP (27).”
InfluentialA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“) for the treatment of lymphoid malignancies, particularly of multiple myeloma (3, 5, 6).”
ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex
Lee, J.-H., & Paull, T. T. (2005) · Science · doi:10.1126/science.1108297 · Cited by 1,424 · cited 1×
“Following the activation of ATM, the MRN complex is required to maintain ATM activation (41).”
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064 · cited 1×
“The 3¶ ssDNA overhang is then rapidly bound by RPA, a protein complex that associates with ssDNA (25).”
Changes in chromatin structure and mobility in living cells at sites of DNA double-strand breaks
Kruhlak, M. J., Celeste, A., Dellaire, G., Fernandez-Capetillo, O., Müller, W. G., McNally, J. G., Bazett-Jones, D. P., & Nussenzweig, A. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200510015 · Cited by 518 · cited 1×
“A possible scenario is that the proteasome may be required to overcome the nucleosome/chromatin barrier to resection (47, 48).”
Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes
Greenberg, R. A., Sobhian, B., Pathania, S., Cantor, S. B., Nakatani, Y., & Livingston, D. M. (2006) · Genes & Development · doi:10.1101/gad.1381306 · Cited by 308
THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Cited by
Doil, C., Mailand, N., Bekker-Jensen, S., Menard, P., Larsen, D. H., Pepperkok, R., Ellenberg, J., Panier, S., Durocher, D., Bartek, J., et al. (2009) · Cell · doi:10.1016/j.cell.2008.12.041 · Cited by 934
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Thompson, L. H. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2012.06.002 · Cited by 357
RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair
Galanty, Y., Belotserkovskaya, R., Coates, J., & Jackson, S. P. (2012) · Genes & Development · doi:10.1101/gad.188284.112 · Cited by 314
“…that they may promote DDR signaling as well as DDR-dependent protein turnover and HR (Ustrell et al. 2002; Blickwedehl et al. 2007; Jacquemont and Taniguchi 2007; Murakawa et al. 2007; Shi et al. 2008; Motegi et al. 2009; Al-Hakim et al. 2010; BenAroya et al. 2010; Levy-Barda et al. 2011).”
BackgroundHomologous recombination in cancer development, treatment and development of drug resistance
Helleday, T. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq064 · Cited by 291
Metadata
- Authors
- Murakawa, Y., Sonoda, E., Barber, L. J., Zeng, W., Yokomori, K., Kimura, H., Niimi, A., Lehmann, A., Zhao, G. Y., Hochegger, H., Boulton, S. J., & Takeda, S.
- Venue
- Cancer Research
- Published
- 2007-09-15
- Volume
- 67
- Issue
- 18
- Pages
- 8536-8543
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2096626023
- Cited by
- 106
- References
- 8
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-1166
- The paper
- Murakawa, Y., Sonoda, E., Barber, L. J., Zeng, W., Yokomori, K., Kimura, H., Niimi, A., Lehmann, A., Zhao, G. Y., Hochegger, H., Boulton, S. J., & Takeda, S. (2007). Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-1166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.